Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression

PUBT · 1d ago
Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression
  • Rhelion Life Sciences, via Filament Health, signed a licence agreement with University Health Network to supply botanical psilocybin candidate PEX010.
  • PEX010 will be used in PSI-PARK, an investigator-initiated randomized clinical trial testing psilocybin for depression in Parkinson’s disease.
  • University Health Network sponsors the trial, led by principal investigator Joshua Rosenblat; Filament is not responsible for trial conduct.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.